Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial.
about
FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experienceRecent progress in pancreatic cancerNeoadjuvant radiotherapeutic strategies in pancreatic cancerCurrent therapeutic strategies for advanced pancreatic cancer: A review for cliniciansManagement of pancreatic cancer in the elderlyLate gastrointestinal tissue effects after hypofractionated radiation therapy of the pancreasPancreatic cancer: optimizing treatment options, new, and emerging targeted therapiesAdvances in systemic therapy for advanced pancreatobiliary malignanciesManagement of borderline and locally advanced pancreatic cancer: where do we stand?Emergence of stereotactic body radiation therapy and its impact on current and future clinical practiceCirculating tumor cells in the diagnosis and management of pancreatic cancerPerspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancerAdjuvant, neoadjuvant, and experimental regimens in overcoming pancreatic ductal adenocarcinomaGenetic factors affecting patient responses to pancreatic cancer treatmentReview of endoscopic radiofrequency in biliopancreatic tumours with emphasis on clinical benefits, controversies and safetyAdvances in chemotherapy for pancreatic cancerThe Targeted SMAC Mimetic SW IV-134 is a strong enhancer of standard chemotherapy in pancreatic cancerA Multidisciplinary Approach to Pancreas Cancer in 2016: A Review.Radiation dose ≥54 Gy and CA 19-9 response are associated with improved survival for unresectable, non-metastatic pancreatic cancer treated with chemoradiation.A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma.Phase II clinical trial of induction chemotherapy with fixed dose rate gemcitabine and cisplatin followed by concurrent chemoradiotherapy with capecitabine for locally advanced pancreatic cancer.A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer.Is concomitant radiotherapy necessary with gemcitabine-based chemotherapy in pancreatic cancer?Gemcitabine and S-1 combination chemotherapy versus gemcitabine alone for locally advanced and metastatic pancreatic cancer: a meta-analysis of randomized controlled trials in Asia.Intravenous ω-3 Fatty Acids Plus Gemcitabine.A phase I/II study of fixed-dose-rate gemcitabine and S-1 with concurrent radiotherapy for locally advanced pancreatic cancer.Correlation of 18F-Fluorodeoxyglucose Positron Emission Tomography Parameters with Patterns of Disease Progression in Locally Advanced Pancreatic Cancer after Definitive Chemoradiotherapy.Combination therapy with gemcitabine and nab-paclitaxel for locally advanced unresectable pancreatic cancer.Treatment outcomes of concurrent hyperthermia and chemoradiotherapy for pancreatic cancer: Insights into the significance of hyperthermia treatmentCombination of dasatinib and gemcitabine reduces the ALDH1A1 expression and the proliferation of gemcitabine-resistant pancreatic cancer MIA PaCa-2 cells.Pancreatic adenocarcinoma response to chemotherapy enhanced with non-invasive radio frequency evaluated via an integrated experimental/computational approach.Challenges in using ¹⁸F-fluorodeoxyglucose-PET-CT to define a biological radiotherapy boost volume in locally advanced pancreatic cancerRadiosensitization of Pancreatic Cancer Cells In Vitro and In Vivo through Poly (ADP-ribose) Polymerase Inhibition with ABT-888.Therapeutic options for the management of pancreatic cancer.Combined inhibition of Wee1 and PARP1/2 for radiosensitization in pancreatic cancer.Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Irreversible electroporation in locally advanced pancreatic cancer: potential improved overall survival.S-1 plus gemcitabine chemotherapy followed by concurrent radiotherapy and maintenance therapy with S-1 for unresectable pancreatic cancer.Neoadjuvant treatment of borderline resectable and non-resectable pancreatic cancer.The combined effect of individual and neighborhood socioeconomic status on cancer survival rates
P2860
Q24622390-EB534258-711C-4241-96FB-F1655D883AA9Q24626346-B59A62D6-6588-43BA-B5B8-390DEA57039BQ26766686-B1679C4A-8F15-460D-A562-A39C0333D21EQ26767041-1237F725-E4EB-4B26-A43D-E52C91D094C1Q26774639-7F6E08C0-65EB-4911-8835-30E755954203Q26785731-D3E70368-39C6-4898-ABA4-1BB79DFAE478Q26799714-0F872185-1AB9-4BA7-ABEF-89572683E8E0Q26822703-2E089FE5-CA20-4AD2-ADF9-9A2E09481E9BQ26825414-D57AD7DE-FDC5-4CDA-B542-D6309F7ECB03Q27015651-4ADD02B9-EE90-4D33-8FE8-3FD7574278E8Q27027711-C6FE659E-CFD9-4CDA-90F8-5187D930E635Q28066320-2F6FCD96-FD76-4930-8679-5136AF68F49FQ28074614-BE77C041-560E-4D73-95B1-964B84D47C9AQ28075293-960BFE69-684E-45E0-97BE-49269E15BF4CQ28077731-8785F5DC-9BE5-40B9-8EED-EBD2D0A02E6FQ28085711-62496B89-D0A6-4399-9F10-B91DD2EAE119Q28468300-0C9E0543-8F49-4068-9A1C-D97692D6D19AQ30238706-AE70C2BA-78F6-4A96-867F-92B27A8A220DQ30423279-53AED77A-35C9-49F7-AEFA-2814B0B2A004Q33401476-FFC1CE29-4188-4340-899F-6F0CE6181098Q33402401-6F05F891-869C-4575-AC5D-AD23E90E7DA7Q33408075-88A56C66-496A-468E-98A6-848129ABA7DAQ33419384-294BDC94-7BEA-4968-B017-90EEB1D76AA7Q33421322-FE474581-392E-48A8-9AE9-B9224FAEE902Q33424793-1E59E9B8-6C92-49EF-B3D2-816465D0C66AQ33424803-C6530538-2CFB-4480-A34B-FC07E9EDFC5AQ33676692-D2E053A7-9E34-415B-94C5-BF3EABC84045Q33748302-3589D1C5-9B57-4CFA-AD75-65363B89C145Q33750784-67C8BC8E-E4E2-4125-89CB-294BF180CB43Q33778101-88E791FD-B197-4ECD-9B1F-C20F503AE783Q33793966-EDC2AD9D-3011-47E0-AD02-F78D74735A8DQ33833200-E8FDCEA6-B3F2-448F-BE54-75F3B6380D83Q34092001-3F16FCEB-4BC4-48D9-A6C5-15637A3075D3Q34093776-919CC18C-2C23-42CE-BB31-97A92519D46FQ34287982-3883BD47-C57A-48BF-8F1A-5FDF7A930965Q34301038-6A560269-5264-46CE-9570-44070BC59581Q34310131-39B2B5FF-61BF-440C-B8E4-6CA4FEA5090CQ34326711-9C2AD754-A822-4A29-BF70-BC9A55EACB13Q34357427-7314B9F3-DE60-4FBA-8F7E-545F49C327CAQ34407878-A0EB84D1-F4D2-45AA-99B3-238BF7811B79
P2860
Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Gemcitabine alone versus gemci ...... perative Oncology Group trial.
@ast
Gemcitabine alone versus gemci ...... perative Oncology Group trial.
@en
type
label
Gemcitabine alone versus gemci ...... perative Oncology Group trial.
@ast
Gemcitabine alone versus gemci ...... perative Oncology Group trial.
@en
prefLabel
Gemcitabine alone versus gemci ...... perative Oncology Group trial.
@ast
Gemcitabine alone versus gemci ...... perative Oncology Group trial.
@en
P2093
P2860
P356
P1476
Gemcitabine alone versus gemci ...... perative Oncology Group trial.
@en
P2093
Al B Benson
Christopher H Crane
Higinia Cardenes
Joanna M Brell
Lynne Wagner
Patrick Flynn
Patrick J Loehrer
Ramesh K Ramanathan
Steven R Alberts
P2860
P304
P356
10.1200/JCO.2011.34.8904
P407
P50
P577
2011-10-03T00:00:00Z